Abbott atrasentan filing delay
Executive Summary
Abbott will not file NDA for oncologic agent atrasentan (ABT-627) until 2004, following the failure of drug to reach its primary endpoint of time-to-progression in a Phase III trial evaluating patients with advanced metastatic hormone-refractory prostate cancer. Abbott previously hoped to file in late 2003 (1"The Pink Sheet" July 2, 2001, p. 22)...